We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MIT.WS
12301
DELISTED
Mason Industrial Technology, Inc. Redeemable warrants, exercisable for one share of Class A common stock for $11.50 per share
MIT.WS
$21K ﹤0.01%
149,121
SBII.WS
12302
DELISTED
Sandbridge X2 Corp. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
SBII.WS
$21K ﹤0.01%
264,688
-10,784
-4% -$2.73K
CLPS icon
12303
CLPS Inc
CLPS
$25.8M
$20K ﹤0.01%
+12,544
New +$22.4K
LRMR icon
12304
CALL
Larimar Therapeutics
LRMR
$453M
$20K ﹤0.01%
10,200
-7,600
-43% -$22.5K
LVO icon
12305
CALL
LiveOne
LVO
$57.2M
$20K ﹤0.01%
+2,280
New +$18.7K
LXEH
12306
Lixiang Education Holding
LXEH
$3.39M
$20K ﹤0.01%
+51
New +$33K
RMTI icon
12307
Rockwell Medical
RMTI
$29.2M
$20K ﹤0.01%
1,532
+1,357
+775% +$35.9K
SLNO
12308
CALL
DELISTED
Soleno Therapeutics
SLNO
$20K ﹤0.01%
7,340
-4,987
-40% -$13.8K
SCNX
12309
Scienture Holdings
SCNX
$18.8M
$20K ﹤0.01%
880
-332
-27% -$8.37K
NVACW
12310
DELISTED
NorthView Acquisition Corporation Warrant
NVACW
$20K ﹤0.01%
176,952
-3,599
-2% -$548
CNGLW
12311
DELISTED
Canna-Global Acquisition Corp Warrant
CNGLW
$20K ﹤0.01%
252,300
TRVN
12312
PUT
DELISTED
Trevena, Inc.
TRVN
$20K ﹤0.01%
77
-1
-1% -$220
SCTL
12313
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$20K ﹤0.01%
25,478
-20,063
-44% -$21.6K
DMS
12314
DELISTED
Digital Media Solutions, Inc.
DMS
$20K ﹤0.01%
+1,171
New +$39.6K
APTO
12315
DELISTED
Aptose Biosciences, Inc.
APTO
$20K ﹤0.01%
60
+33
+122% +$15.8K
LVRAW
12316
DELISTED
Levere Holdings Corp. Warrant
LVRAW
$20K ﹤0.01%
250,200
-98
-0% -$19
ATHX
12317
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$20K ﹤0.01%
3,136
-2,492
-44% -$27.6K
ZNB
12318
Zeta Network Group
ZNB
$2.02M
0
FRMM
12319
PUT
Forum Markets
FRMM
$80.4M
$19K ﹤0.01%
6
-4
-40% -$22.9K
BTCS icon
12320
BTCS Inc
BTCS
$55.7M
$19K ﹤0.01%
+12,860
New +$35.8K
DSS icon
12321
DSS Inc
DSS
$5.68M
$19K ﹤0.01%
+2,856
New +$22.7K
GYRE icon
12322
PUT
Gyre Therapeutics
GYRE
$708M
$19K ﹤0.01%
+1,400
New +$9.3K
NEPH icon
12323
Nephros
NEPH
$50.3M
$19K ﹤0.01%
+12,123
New +$32.7K
NRXP icon
12324
PUT
NRX Pharmaceuticals
NRXP
$140M
$19K ﹤0.01%
3,210
-4,290
-57% -$56.4K
SNTG icon
12325
Sentage Holdings
SNTG
$5.55M
$19K ﹤0.01%
6,394
+2,873
+82% +$10.2K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.